characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2023-08-08T00:19:49Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2023-08-08T00:19:49Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA111379080
characteristics.characteristic: External Id
characteristics.text: UNIVERSITY OF MANCHESTER
characteristics.characteristic: INSDC center name
characteristics.text: 2023-08-08T00:19:49Z
characteristics.characteristic: INSDC first public
characteristics.text: 2023-08-08T00:19:49Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS13476065
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-12195:Sample 39
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.characteristic: broker name
characteristics.text: YUMM2.1
characteristics.characteristic: cell_line
characteristics.text: house mouse
characteristics.characteristic: common name
characteristics.text: Protocols: This submission studied the inhibition of PARP14 under IFNγ stimulation in three cell lines. A375 (https://www.cellosaurus.org/CVCL_0132) human melanoma cell line was maintained in DMEM (high glucose) medium. MC38 (https://www.cellosaurus.org/CVCL_B288) mouse colon cancer cell line was maintained in RPMI-1640 (Sigma-Aldrich) medium. YUMM2.1 (https://www.cellosaurus.org/CVCL_JK30) mouse melanoma cell line was maintained in RPMI-1640 (Sigma-Aldrich) medium. All growth media were supplemented with 10% fetal bovine serum (FBS; Life Technologies), 1% penicillin-streptomycin (P/S; Sigma-Aldrich) and 0.1% by volume of DMSO (solvent for the inhibitors). All cells were maintained under standard conditions at 37°C in a 5% CO2 humidified incubator and passaged before reaching confluency. Cell cultures were routinely tested for mycoplasma contamination by PCR. For chronic IFNγ stimulation, human cells (A375) were treated with 20 IU/ml, mouse cells (YUMM2.1 and MC38) with 50 IU/ml, replacing medium and IFNγ every 72 h with passaging of cells as necessary for 2 weeks. PARP14 inhibition was with 100 nM RBN012759 or 500 nM RBN012811 for the last 48 h. Recombinant human IFNγ (PHC4031) and recombinant mouse IFNγ (PMC4031) were purchased from Gibco and used at the indicated concentrations. The PARP14 inhibitors RBN012759 and RBN012811 were kindly provided by Ribon Therapeutics and used at the indicated concentrations. This submission studied the inhibition of PARP14 under IFNγ stimulation in three cell lines. A375 (https://www.cellosaurus.org/CVCL_0132) human melanoma cell line was maintained in DMEM (high glucose) medium. MC38 (https://www.cellosaurus.org/CVCL_B288) mouse colon cancer cell line was maintained in RPMI-1640 (Sigma-Aldrich) medium. YUMM2.1 (https://www.cellosaurus.org/CVCL_JK30) mouse melanoma cell line was maintained in RPMI-1640 (Sigma-Aldrich) medium. All growth media were supplemented with 10% fetal bovine serum (FBS; Life Technologies), 1% penicillin-streptomycin (P/S; Sigma-Aldrich) and 0.1% by volume of DMSO (solvent for the inhibitors). All cells were maintained under standard conditions at 37°C in a 5% CO2 humidified incubator and passaged before reaching confluency. Cell cultures were routinely tested for mycoplasma contamination by PCR. For chronic IFNγ stimulation, human cells (A375) were treated with 20 IU/ml, mouse cells (YUMM2.1 and MC38) with 50 IU/ml, replacing medium and IFNγ every 72 h with passaging of cells as necessary for 2 weeks. PARP14 inhibition was with 100 nM RBN012759 or 500 nM RBN012811 for the last 48 h. Recombinant human IFNγ (PHC4031) and recombinant mouse IFNγ (PMC4031) were purchased from Gibco and used at the indicated concentrations. The PARP14 inhibitors RBN012759 and RBN012811 were kindly provided by Ribon Therapeutics and used at the indicated concentrations. Total RNA was isolated using the RNAeasy mini kit. RNA integrity was assessed on the Agilent 2200 TapeStation (Agilent Technologies). TruSeq Stranded mRNA assay (Illumina)
characteristics.characteristic: description
characteristics.text: melanoma
characteristics.characteristic: disease
characteristics.text: not applicable
characteristics.characteristic: isolate
characteristics.text: Mus musculus
characteristics.characteristic: organism
characteristics.text: Mus musculus
characteristics.characteristic: organism
characteristics.text: skin
characteristics.characteristic: organism part
characteristics.text: Mus musculus
characteristics.characteristic: scientific_name
characteristics.text: interferon gamma
characteristics.characteristic: stimulus
characteristics.text: Sample 39
characteristics.characteristic: title